PRESENTATION

Q3 2022 — Presentation

Q3 2022PDF · 31 pages2.6 MB
Merck
Q3 2022 Earnings
October 27, 2022

-- 1 of 31 --

Agenda
2
Strategy and
Business Update
Rob Davis
President & Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 31 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will
receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).

-- 3 of 31 --

Strategy &
Business Update
Rob Davis
President & Chief Executive Officer

-- 4 of 31 --

Delivered on our key strategic priorities in Q3
5
Achieved strong commercial and
financial performance
Advanced the pipeline to meet patient
unmet need
Executed on strategic business
development to enhance pipeline
Created long-term value for patients
and shareholders

-- 5 of 31 --

Exceptional Q3 sales and underlying earnings growth 1
6
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Beginning in 2022, Merck no longer excludes expenses for upfront and milestone payments related to collaborations and
licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. For 2020, non-GAAP results have been recast to
include $4.2 billion of incremental R&D expenses, which reduced EPS by $1.56. For 2021, non-GAAP results have been recast to include $1.7 billion of incremental R&D expense, which reduced EPS by
$0.65. For 3Q 2022 and full year 2022, non-GAAP results include $690 million of R&D expense, or an estimated $0.22 of negative impact to EPS, driven by collaborations and license agreements with
Orion, Orna and Moderna recorded in in the third quarter of 2022. 3. GAAP EPS of $1.28.
$41.5B
+6%
$48.7B
+17%
GUIDANCE
RANGE
$57.5B-$58.5B
$15.0B
+14%
Ex-LAGEVRIO, +10%
Worldwide Sales
$1.85
+4%
Non-GAAP EPS2,3
2020 	2021 	2022
$41.5B
+6%
$48.7B
+17%
2020 	2021 	2022
$2.97
$5.37
GUIDANCE
RANGE
$58.5B-$59.0B
GUIDANCE
RANGE
$7.32-$7.37
Full Year Revenue
Full Year Non-GAAP EPS2

-- 6 of 31 --

Advancing deep pipeline across multiple therapeutic areas
7
Cardiovascular 	Oncology
• 	Presented encouraging
results at ESMO across
our broad portfolio and
promising pipeline
• 	Announced positive
results for the Phase 3
STELLAR trial
evaluating sotatercept
as an add-on to stable
background therapy in
patients with
pulmonary arterial
hypertension
• 	Received FDA Fast
Track Designation for
anticoagulant
candidate MK-2060
(Factor XI) for patients
with end-stage renal
disease
Vaccines
• 	Advanced population-
specific approach to
invasive pneumococcal
disease
– Launched
VAXNEUVANCE in
the pediatric setting
in the U.S.
– Progressing Phase 3
trials evaluating V116
in adults
HIV
• 	Announced path
forward for islatravir
for the treatment of
HIV
• 	Committed to helping
address unmet needs in
HIV treatment and
prevention

-- 7 of 31 --

Making progress on our commitment to deliver value to society,
which will in turn, create value for shareholders
8
Published ESG Progress Report
• 	Highlighted key initiatives including:
– 	Providing 91.5 million doses of HPV
vaccines in Gavi-supported countries
– 	Advancing our goal to achieve
carbon neutrality by 2025
– 	Supporting ESG-related projects
and partnerships through the use
of funds from the issuance of our
$1 billion sustainability bond
Access to
health Employees
Environmental
sustainability
Ethics
& values

-- 8 of 31 --

Appreciation for Ken Frazier as he retires from Merck’s Board
9
For decades, Ken has embodied Merck’s
core principles and values, anchored by a
singular focus on creating meaningful
value for our patients, employees,
communities and shareholders.
Ken is a once-in-a-generation leader, and
his positive impact on our company and
patients everywhere will reverberate for
decades.
Tom Glocer, lead independent director

-- 9 of 31 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 10 of 31 --

Excellent Q3 performance led by Human Health
11
Merck
WORLDWIDE SALES1,2
$15.0B+14% growth
+10% ex-LAGEVRIO 3
+14% ex-exchange, ex-LAGEVRIO 4
$13.0B
+13% growth
+9% ex-LAGEVRIO3
+15% ex-exchange, ex-LAGEVRIO4
Human Health 3
$1.4B
-3% decrease
+4% ex-exchange
Animal Health
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue 3. Excludes LAGEVRIO sales of $436 million in the quarter
4. Excludes LAGEVRIO sales of $436 million in the quarter and foreign exchange

-- 11 of 31 --

Oncology: KEYTRUDA momentum driving strong global growth
12	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $5.4B increased 26%
year-over-year, driven by strong global
demand and uptake in new indications
– In the U.S., growth of 29% reflects strong
momentum in metastatic indications as well as
increased uptake in earlier-stage cancer
launches including high-risk, early-stage TNBC
– Ex-U.S., 21% increase driven by global uptake
in NSCLC as well as HNSCC and advanced RCC
• Strong uptake from new launches in high-risk,
early-stage TNBC and RCC in key European
markets
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
3Q20 	3Q21 	3Q22
$4.5B
+21%
$3.7B
+21%
$5.4B
+26%

-- 12 of 31 --

Oncology: Sustained momentum from key products
• Lynparza 1 sales increased 23%, with growth
driven by continued demand for the adjuvant
treatment of certain patients with gBRCAm,
HER2-negative high-risk early-stage breast
cancer based on OlympiA
• Lenvima 2 sales grew 11% driven by demand
following recent launches in RCC and
endometrial cancer, partially offset by
shipment timing in China
• WELIREG experiencing strong uptake in
patients with certain VHL-associated tumors
$248M
+34%	$178M
+62%
$275M
+17%
$181M
+15%
$151M
+57%
$231M
+33%
13	Growth rates exclude the impact of foreign exchange.
1 In collaboration with AstraZeneca. 2 In collaboration with Eisai
3Q20 	3Q21 	3Q22
3Q20 	3Q21 	3Q22
$246M
+25%	$196M
+58%
$284M
+23%
$188M
+30%	$142M
+29%
$202M
+11%

-- 13 of 31 --

Vaccines: GARDASIL growth remains very strong
14
• GARDASIL sales of $2.3B increased 20% year-
over-year primarily driven by strong
underlying demand outside the U.S. and
increased supply
– Ex-U.S., reflects demand driven growth,
particularly in China, and increased supply
– U.S. sales growth was driven by timing of CDC
purchases
Increase/decrease in sales exclude the impact of foreign exchange.
$1.2B
+78%
$656M
-24%
$1.7B
+40%
3Q20 	3Q21 	3Q22
$2.0B
+63%
$1.2B
-10%
$2.3B
+20%

-- 14 of 31 --

Hospital: Robust global demand across key products
15
• BRIDION sales of $423M increased 22%
primarily due to greater share among
neuromuscular blockage reversal agents
and increase in surgical procedures
• PREVYMIS sales grew 29%, driven by
continued strong global demand
• ZERBAXA benefiting from completion
of global resupply
$387M
+67%
$224M
-18%
$426M
+15%
3Q20 	3Q21 	3Q22
$369M
+15%$320M
+13%
$423M
+22%
$93M
+41%$63M
+67%
$103M
+18%
3Q20 	3Q21 	3Q22
$96M
+22%
$77M
+69%
$114M
+29%
Growth rates exclude the impact of foreign exchange.

-- 15 of 31 --

Animal Health: Solid Livestock and Companion Animal performance
16
• Animal Health sales increased 4% to $1.4B
– Livestock sales grew 4% due to poultry
products and ruminant technology solutions
– Companion Animal sales increased 4%, driven
by BRAVECTO parasiticide line of products,
partially offset by supply challenges for certain
vaccines
Growth rates exclude the impact of foreign exchange.
$1.5B
+27%
$1.1B
+3%
$1.5B
+5%
3Q20 	3Q21 	3Q22
$1.4B
+14%
$1.2B
+12%
$1.4B
+4%

-- 16 of 31 --

Q3 2022 continuing operations non-GAAP financial results summary 1:
Delivered strong revenue and EPS growth
Q3 2022 	Q3 2021 	Change Change
Ex-FX
Sales 	$15.0 	$13.2 	+14% 	+18%
Non-GAAP Gross
Margin 77.0% 	76.8% 	+0.2pts 	-0.4pts
Non-GAAP Operating
Expenses 2 $6.0 	$4.7 	+28% 	+32%
Non-GAAP Tax Rate 	13.6% 	12.8% 	-0.8pts 	N/A
Non-GAAP EPS3 $1.85 	$1.78 	+4% 	+7%
$ in billions, except EPS amounts
17
1. Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the press release. Non-GAAP results for 2021 have been recast to conform to
presentation changes implemented in 2022.
2. Non-GAAP results include $690 million of R&D expense, recorded in the third quarter of 2022, for collaborations and licensing agreements with Moderna, Orna and Orion, or an estimated $0.22 of
negative impact to EPS 3. Q3 2022 GAAP EPS of $1.28.

-- 17 of 31 --

Merck updated full-year 2022 guidance
1. GAAP Gross Margin Rate: ~70%. 2. GAAP Operating Expenses: $22.5 to $22.9 billion. 3. GAAP Tax Rate: ~11% 4. The GAAP to non-GAAP reconciliation is available in Merck’s Q3 2022 earnings
release 5. Beginning in 2022, Merck no longer excludes expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval
assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Prior periods have been recast to reflect this change. 6. R&D expense related to collaboration and
licensing agreements with Moderna, Orna and Orion recorded in 3Q 2022
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $57.5B to $58.5B
+18% to +20% (+21% to +23% ex-FX)
$58.5B to $59.0B
+20% to +21% (+24% to +25% ex-FX)
• 	~16% growth excluding LAGEVRIO and FX impact
• 	Includes $5.2 to $5.4B of LAGEVRIO revenue
• 	Assumes ~4% negative FX impact (vs. prior ~3%
negative FX impact)
Non-GAAP
Gross Margin Rate 1 	74.0% - 74.5% 	74.0% - 74.5%
Non-GAAP
Operating Expenses2 	$20.5B to $21.5B 	$21.3B to $21.7B
• 	Now includes $250M related to Moderna option
exercise; Full-year 2022 includes $690 million of R&D
expense related to collaboration and licensing
agreements6
Other (Income) / Expense 	~$500M of expense 	~$500M of expense
Tax Rate 3 	~13.5-14.5% 	~14%
Shares Outstanding 	~2.54B 	~2.54B
GAAP EPS 	$5.89 to $5.99 	$5.68 to $5.73
Non-GAAP EPS4,5 	$7.25 to $7.35 	$7.32 to $7.37
• 	Assumes ~4% negative FX impact (vs. prior ~3%
negative FX impact)
• 	Full year 2022 includes $0.22 of R&D expense related
to collaboration and licensing agreements6
18

-- 18 of 31 --

Key modeling considerations
19
Other Revenue
• 	FX continues to be a headwind, particularly for products
with a larger portion of ex-US sales, such as in Animal
Health
• 	Includes ongoing supply sales to Organon, effects from
revenue hedging program and out-license receipts
FX
Pneumococcal
• 	Expect continued negative impact to PNEUMOVAX23 in the
U.S. as the market shifts toward newer pneumococcal
conjugate vaccines

-- 19 of 31 --

20
Continue to prioritize
investments in our
pipeline and business
to realize value
of near- and long-term
opportunities
$3.0
$1.1
$1.7
$0.8
$0.0
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
$ Billions1
1. Reflects Q3 spend
Remain committed to balanced capital allocation strategy
Capital allocation order of priority

-- 20 of 31 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 21 of 31 --

Driving value for patients and shareholders by progressing our pipeline
22
Key regulatory milestones
since the last earnings call:
Key data & clinical advancements
since the last earnings call:
• 	In the US:
o The FDA accepted submission of New Drug
Application and granted priority review for Lynparza1
in combination with abiraterone and prednisone or
prednisolone in mCRPC based on PROpel, as well as
granted Fast Track designation for
investigational anticoagulant MK-2060 in patients
with ESRD
• 	In the EU:
o Received approval for Lynparza as adjuvant
treatment in certain patients with gBRCAm, HER2-
negative, high-risk early breast cancer based on
OlympiA, as well as for VAXNEUVANCE in pediatrics
• 	In China:
o Received approval for KEYTRUDA in 2L HCC based
on KN-394, as well as for Lynparza in combination
with bevacizumab for maintenance therapy for
certain patients with ovarian cancer based on
PAOLA-1
• 	In Japan:
o Received 4 new approvals for KEYTRUDA (KN-522,
KN-564, KN-826 and KN-716) as well as 1 new
approval for Lynparza as adjuvant treatment in
certain patients with gBRCAm, HER2-
negative, high-risk early breast cancer based on
OlympiA, 1 new approval for Koselugo 1 in
neurofibromatosis type-1 in pediatrics, and 1 new
approval for V114 in adults
• 	Announced positive top-line results from pivotal
Phase 3 STELLAR trial evaluating sotatercept as an
add-on to stable background therapy for the
treatment of adults with PAH
• 	Presented data across our broad oncology portfolio
at ESMO, including for KEYTRUDA (KN-189 and
KN-407), Lynparza (SOLO- 1 and PAOLA-1), as well
as KEYTRUDA + Padcev (KN-869 / EV-103)2
• 	Announced path forward for islatravir, including
new Phase 3 clinical program with lower dose of
daily oral islatravir in combination with doravirine,
as well as a new Phase 2 clinical trial studying a
once-weekly combination treatment regimen of
islatravir and lenacapavir3
• 	Provided real-world data updates with our partner
Ridgeback Biotherapeutics based on the
PANORAMIC and Clalit studies
1. In collaboration with AstraZeneca 2.In collaboration with Seagen and Astellas 3. In collaboration with Gilead

-- 22 of 31 --

23
Potential to transform the treatment of adult patients
with pulmonary arterial hypertension
• 	Positive topline results from Phase 3 STELLAR
trial evaluating sotatercept added to currently
approved background therapy in Pulmonary
Arterial Hypertension
– 	Profound effect on primary efficacy outcome
measure of improvement in 6MWD from baseline
at 24 weeks
– 	8 out of 9 secondary efficacy outcome measures
achieved statistical significance
• 	Additional Phase 3 trials evaluating sotatercept
in patients with Pulmonary Arterial
Hypertension include ZENITH and HYPERION
• 	Sotatercept is also being evaluated in the Phase
2 CADENCE trial, in patients with Cpc-PH due to
HFpEF
• 	Ongoing Phase 2/3 trials studying MK-5475 an
investigational, inhaled sGC stimulator in PAH

-- 23 of 31 --

Real-world evidence (RWE) supports the role of LAGEVRIO as an
important option in treating adults at high risk for severe COVID-19
24
• 	Approximately 2.5 million people globally have
received LAGEVRIO for the treatment of COVID-19
• 	Data from recent RWE studies conducted across
different geographies provide insight into patient
experience with LAGEVRIO, suggesting:
– 	faster time to recovery and to initial alleviation of
symptoms, among highly-vaccinated adults at risk
for severe COVID-19, vs. usual care alone 1
– 	reduced risk for hospitalization and mortality
among patients aged 65 years and older 2
• 	LAGEVRIO remains an important treatment
option as the pandemic continues to evolve with
new variants and varying degrees of vaccine
effectiveness across the globe
• 	Initiated Phase 2 trial for the treatment of
Respiratory Syncytial Virus based on the promising
clinical profile of LAGEVRIO
1. Butler et al. Preprint, 4 Oct 2022. Available at SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4237902. In the preliminary analysis of the PANORAMIC study, a UK-based clinical trial
sponsored by the University of Oxford, the primary endpoint of reduction of hospitalizations and deaths within 28 days of randomization, compared to usual care, was not met.
2. The Clalit trial, an observational, retrospective cohort study, evaluated data obtained from the electronic medical records of members of Clalit Health Services. The study assessed the real-world
effectiveness of LAGEVRIO in preventing severe COVID-19 outcomes in patients 40 years of age and older estimated to be at high risk of progression to severe disease, who were infected by the
Omicron variant and were not eligible for ritonavir-boosted nirmatrelvir therapy due to drug-drug interactions or impaired kidney function. No evidence of benefit was found in younger adults ages 40
to 64 years

-- 24 of 31 --

Significant advancements across our broader pipeline and portfolio
25
HIV
• 	Initiated new Phase 3 clinical program
evaluating a once-daily oral
combination of doravirine and a lower
dose of islatravir for the treatment of
people with HIV-1 infection
• 	Announced plans to resume Phase 2
study with Gilead, evaluating a weekly
oral combination treatment regimen
of islatravir and lenacapavir in adults
with HIV-1 infection who are
virologically suppressed is resuming
with a lower dose of islatravir
• 	Prioritizing an internal novel NRTTI
compound for development in the
PrEP setting
Vaccines
• 	In China, received broadened
approval based on age from the
National Medical Products
Administration for GARDASIL-9 for
use in girls and women ages 9 to 45
• 	In the EU, received approval for
VAXNEUVANCE in infants, children
and adolescents 6 weeks to less than
18 years of age for the prevention of
invasive disease, pneumonia and
acute otitis media caused by
Streptococcus pneumoniae
RNA Technologies
• 	Executing on business development
and licensing strategy
– 	Collaboration with Orna
Therapeutics on its circular RNA
technology

-- 25 of 31 --

Continuing to build on strong momentum in oncology
26
Quarterly highlights
• 	Important data at ESMO:
‒ 	Showcased long-term survival
benefit for KEYTRUDA in NSCLC,
melanoma and head and neck
cancers as well as LYNPARZA in
ovarian cancer
‒ 	Presented data in earlier stage
settings, building on our
expansive efforts
‒ 	Presented first time positive data
in collaboration with Seagen and
Astellas for KEYTRUDA plus
enfortumab vedotin-ejfv in locally
advanced / metastatic urothelial
cancer
• 	Received priority reviewfrom FDA
for Lynparza with abiraterone and
prednisone or prednisolone for
certain patients with metastatic
castration-resistant prostate cancer
Global highlights
• 	Four approvals in Japan for
KEYTRUDA in neoadjuvant /
adjuvant high-risk early-stage TNBC,
adjuvant RCC, stage IIB and IIC
melanoma and cervical cancer
• 	Approval in EU and Japan for
Lynparza for adjuvant treatment of
certain patients with gBRCAm,
HER2-negative, high-risk early
breast cancer
• 	Approval in China for Lynparza for
first line maintenance treatment
with bevacizumab of HRD-positive of
advanced ovarian cancer
Personalized Cancer Vaccines
• 	Exercised option to jointly develop
mRNA-4157 / V940 with Moderna in
melanoma
• 	Complements broad oncology and
vaccine development programs

-- 26 of 31 --

Q&A
Rob Davis
President & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 27 of 31 --

Appendix
28

-- 28 of 31 --

Q3 2022 continuing operations GAAP financial results summary
29
Q3 2022 	Q3 2021 	Change Change
Ex-FX
Sales 	$15.0 	$13.2 	+14% 	+18%
Operating Expenses 	$6.9 	$4.8 	+45% 	+49%
Tax Rate 	9.2% 	13.2% 	-4.0pts 	N/A
GAAP EPS 	$1.28 	$1.80 	-29% 	-25%
$ in billions, except EPS amounts

-- 29 of 31 --

$10.1
$4.5
$6.9
$13.7
$0.0
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$17B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Billions
$1.72 	$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$2.76
$1.40
$1.70
$2.00
$2.30
$2.60
$2.90
2013 	2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022
Dollars per share	
+11% 	+2% 	+2% 	+2% 	+2% 	+2%
+11%
+15%
+7%
Over the past 12 months
Capital investments
2022 to 2026
Commitment to the dividend
30
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
+6%
Order of priority

-- 30 of 31 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V184
Chikungunya Virus
V181
Dengue Fever Virus
Vaccines
Infectious diseases
MK-8189 4
Schizophrenia
Neuroscience
Gefapixant (MK-7264)
Cough (US, EU)
General medicine
General medicine
As of November 3, 2022
V114
Pneumococcal Vaccine, pediatric (JPN)
Vaccines
Infectious diseases
Oncology 	Oncology
MK-1942
Treatment Resistant Depression
MK-3655
NASH
MK-6024
NASH
MK-7075 (miransertib)
Overgrowth Syndrome
MK-8591B (islatravir+MK-8507) 1
HIV-1 Infection
MK-8591D (islatravir+lenacapavir) 2
HIV-1 Infection
KEYTRUDA (MK-3475)
Biliary Tract
CSCC (EU)
Gastric (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
Prostate
SCLC
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-7684A (vibostolimab
+pembrolizumab)
NSCLC
SCLC
MK-4280A (favezelimab
+pembrolizumab)
CRC
Hematological
Malignancies
LENVIMA (MK-7902)
HNSCC
Melanoma
CRC
Esophageal
NSCLC
Gastric
LYNPARZA (MK-7339)
NSCLC
SCLC
WELIREG (MK-6482)
RCC
TUKYSA (MK-7119)
Breast
CRC
MK-3475
(pembrolizumab
subcutaneous)
NSCLC
MK-8591A (doravirine+islatravir) 2
HIV-1 Infection
Molnupiravir (MK-4482) 3
COVID-19 antiviral
KEYTRUDA (MK-3475)
2L HCC (US)
Adjuvant NSCLC (US, EU)
LYNPARZA (MK-7339)
Metastatic 1L Prostate (US, EU, JPN)
MK-0616
Hypercholesterolemia
MK-2060
Cardiovascular
Thrombosis
MK-5475
Pulmonary Arterial Hypertension
MK-7962
Pulmonary Hypertension due to Left
Heart Disease
Cardiovascular
MK-5684
Prostate
MK-5890 (boserolimab)
NSCLC
SCLC
MK-6440
(ladiratuzumab vedotin)
Breast
NSCLC
SCLC
HNSCC
Esophageal
Gastric
Prostate
Melanoma
MK-2870
Neoplasm Malignant
KEYTRUDA (MK-3475)
Advanced Solid Tumors
MK-4280
(favezelimab)
NSCLC
MK-4280A
(favezelimab+pembroli
zumab)
Esophageal
RCC
SCLC
MK-4830
Esophageal
Ovarian
NSCLC
SCLC
RCC
CRC
Melanoma
WELIREG (MK-6482)
Rare Cancers
CRC
Endometrial
Esophageal
Pancreatic
Biliary
HCC
Certain VHL tumors
(EU)
LYNPARZA (MK-7339)
Advanced Solid Tumors
LENVIMA (MK-7902)
Biliary
Glioblastoma
Prostate
SCLC
Pancreas
MK-7684
(vibostolimab)
Melanoma
MK-7684A
(vibostolimab
+pembrolizumab)
Biliary
Cervical
CRC
Esophageal
Breast
HNSCC
HCC
Endometrial
Prostate
Hematological
Malignancies
TUKYSA (MK-7119)
Advanced Solid Tumors
Gastric
Endometrial
NSCLC
Bladder
Biliary
Cervical
mRNA-4157/V940
Melanoma
MK-0482
NSCLC
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
HCC
CRC
SCLC
Melanoma
MK-2140 (zilovertamab
vedotin)
Breast
Gastric
Ovarian
Pancreas
NSCLC
Hematological Malignancies
Broad and innovative pipeline to solve significant unmet medical needs
31
Vaccines
MK-1654 (clesrovimab)
Respiratory Syncytial
Virus
1 On FDA clinical hold 2On FDA partial clinical hold 3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma
Sotatercept (MK-7962)
Pulmonary Arterial Hypertension
Cardiovascular
Infectious diseases
Molnupiravir (MK-4482)
COVID-19 antiviral (EU)
V116
Pneumococcal vaccine,
adult

-- 31 of 31 --